Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

NCT02215967 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Myeloma, Plasma-Cell
Myeloma-Multiple

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells

Sponsor

National Cancer Institute (NCI)